Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Icerguastat - InFlectis BioScience

Next Previous
Drug Profile

Icerguastat - InFlectis BioScience

Alternative Names: IFB-088; selective inhibitor of a holophosphatase - InFlectis BioScience; Sephin1

Latest Information Update: 18 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Medical Research Council
  • Developer Assistance Publique - Hopitaux de Marseille; InFlectis BioScience; Qualissima; Stragen France SAS
  • Class Chlorobenzenes; Guanidines; Small molecules
  • Mechanism of Action PPP1R15A protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Charcot-Marie-Tooth disease; Amyotrophic lateral sclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Amyotrophic lateral sclerosis
  • Phase I Charcot-Marie-Tooth disease
  • Preclinical Multiple sclerosis

Most Recent Events

  • 20 Jan 2025 InFlectis BioScience completes the phase II TRIALS trial in Amyotrophic lateral sclerosis (Combination therapy) in Italy and France (PO) (EUCT2021-003875-32) (NCT05508074)
  • 22 Oct 2024 Icerguastat is still in phase-I trial for Charcot-Marie-Tooth-disease (In volunteers) in France (PO, Capsule) (InFlectis BioScience pipeline, October 2024)
  • 22 Oct 2024 InFlectis BioScience plans a phase II trial for Charcot-Marie-Tooth disease in the US and Europe (InFlectis BioScience pipeline, October 2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top